Business
Gilead Sciences develops and markets medicines for HIV, oncology, liver disease and other serious conditions.
Gilead Sciences: Revenue grew 2.4% to $29.443B from $28.754B. Net income grew 1672.9% to $8.51B from $480M. Free cash flow declined 8.2% to $9.456B from $10.305B. Operating margin expanded 2826 bps to 34.04%. Gilead Sciences's annual comparison also shows free cash flow declined despite revenue growth; stock compensation grew faster than revenue; capital spending grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 2.4%OK
- Profitability — Net income grew 1672.9% to $8.51B from $480MOK
- Cash flow — Free cash flow declined 8.2% to $9.456B from $10.305BWatch
- Margins — Operating margin expanded 2826 bps to 34.04%OK
- Accounting — No overriding statistical warningNote
- Insiders — 1 purchases and 41 salesOK
Where the revenue comes from
Fiscal 2025, as GILEAD SCIENCES, INC. reports it. History and quarterly detail are in the app.
- Product$28.9B
- Royalty, contract and other revenues$527.0M
Leadership changes
From GILEAD SCIENCES, INC.'s own filings, the day they're filed.
- Erin Burkhart · President · appointmenteff. 2025-09-22
- Sandra Patterson · Chief Accounting Officer · departureeff. 2025-03-12
- Merdad V. Parsey · Chief Medical Officer · departureeff. 2024-07-17
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-05-20
- 8-K · Company announcement2026-05-07
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about GILEAD SCIENCES, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.